RCC
Les récepteurs des chimiokines C-C (CCRs) sont un groupe de GPCR qui répondent aux chimiokines, des molécules de signalisation qui guident la migration des cellules immunitaires vers les sites d'inflammation ou d'infection. Les CCR jouent un rôle crucial dans les réponses immunitaires, l'inflammation et le développement de diverses maladies, y compris les troubles auto-immuns et le cancer. La modulation de l'activité des CCR est explorée comme une stratégie thérapeutique pour des affections telles que la polyarthrite rhumatoïde, la sclérose en plaques et l'infection par le VIH. Chez CymitQuimica, nous offrons une gamme de modulateurs de CCR de haute qualité pour soutenir vos recherches en immunologie, inflammation et développement thérapeutique.
154 produits trouvés pour "RCC".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
TBK1 degrader-4
TBK1degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. It effectively inhibits cyst growth, reduces inflammation, and lowers levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1degrader-4 shows potential for research in autosomal dominant polycystic kidney disease (ADPKD).Couleur et forme :Odour SolidZn-DPA-maytansinoid conjugate 1
Zn-DPA-maytansinoid 1 targets checkpoints, shrinks tumors, and heats TME.Formule :C115H145ClN18O31S2Zn2Couleur et forme :SolidMasse moléculaire :2505.83CHS-114
CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.Couleur et forme :Odour LiquidMet-RANTES,human,acetate
Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.Couleur et forme :Odour SolidCKLF1-C27 TFA
CKLF1-C27 peptide activates ERK1/2 via CCR4, competes with CKLF1, promotes HUVEC growth, and has psoriasis research potential.Formule :C153H244F3N39O39Couleur et forme :SolidMasse moléculaire :3310.8CCR8 antagonist 1
CAS :CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.Formule :C26H29N3O5SDegré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :495.59Plozalizumab
CAS :Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study ofDegré de pureté :96.4%Couleur et forme :Transparent LiquidMasse moléculaire :146.02 kDaCCR4 antagonist 3
CAS :Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.Formule :C24H27Cl2N7OCouleur et forme :SolidMasse moléculaire :500.43Bertilimumab
CAS :Bertilimumab (CAT 213; iCo-008), a human monoclonal antibody that targets eotaxin-1 (CCL11), shows promise in the research of allergic disorders [1].Couleur et forme :Liquid2-Methoxyhydroquinone
CAS :2-Methoxyhydroquinone inhibits MAO-A and MAO-B and reduces TNF-α-induced CCL2 production, a precursor for synthesising the Hsp90 inhibitor Geldanamycin.Formule :C7H8O3Degré de pureté :98.25%Couleur et forme :SolidMasse moléculaire :140.14CCR6 antagonist 2
CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.Formule :C19H24N4O4Couleur et forme :SolidMasse moléculaire :372.42INCB 3284 dimesylate
CAS :INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.Formule :C28H39F3N4O10S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :712.76GSK163929
CAS :GSK163929 (compound 122) is an orally active CCR5 antagonist with anti-HIV properties and demonstrates low inhibitory potency against hEGR. Administered at a dosage of 2000 mg/kg/day (i.v., 7 d), it shows no adverse effects in rats, and at 250 mg/kg/day (i.v., 7 d), it is similarly non-toxic in dogs.Formule :C36H40ClF2N5O3SCouleur et forme :SolidMasse moléculaire :696.25BMS-753426
CAS :BMS-753426 is a potent and orally bioavailable antagonist of CCR2 .Formule :C25H33F3N6O2Couleur et forme :SolidMasse moléculaire :506.574HGS004
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. It exhibits potent antiviral activity against various CCR5-tropic HIV-1 strains, including those resistant to other treatments (such as Maraviroc-resistant strains). HGS004 is applicable for research in HIV-1 infection.Couleur et forme :Odour LiquidAplaviroc hydrochloride
CAS :Aplaviroc, a potent CCR5 inhibitor, binds selectively, blocking HIV entry and specific monoclonal antibody attachment in vitro.Formule :C33H44ClN3O6Couleur et forme :SolidMasse moléculaire :614.17PF-232798
CAS :PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.Formule :C29H40FN5O2Couleur et forme :SolidMasse moléculaire :509.66CCR4 antagonist 3 hydrochloride
CAS :Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.Formule :C24H27Cl2N7O·xHClCouleur et forme :SolidVZMC013
VZMC013 is a potent chemical probe targeting the MOR-CCR5 heterodimer, effectively inhibiting HIV-1 entry exacerbated by opioid compounds. It exhibits nanomolar binding affinity to both MOR and CCR5, inhibits CCL5-activated calcium mobilization, and significantly enhances anti-HIV-1BaL activity compared to previously reported bivalent ligands. In TZM-bl cells co-expressing CCR5 and MOR, VZMC013 demonstrates greater inhibition of viral infection than in cells expressing only CCR5. Additionally, VZMC013 blocks HIV-1 entry into peripheral blood mononuclear cells (PBMC) in a concentration-dependent manner and more effectively inhibits opioid-accelerated HIV-1 entry in phytohemagglutinin-activated PBMC than in opioid-free environments.Formule :C65H92F2N10O10Masse moléculaire :1211.48CMKLR1 antagonist 1
CMKLR1 antagonist 1 (compound S-26d) is a potent, orally active antagonist of the chemokine-like receptor 1 (CMKLR1), exhibiting a pIC50 of 7.44 in hCMKLR1-Couleur et forme :Odour Solid
